CRISPR Therapeutics Approaches Its First Earnings With Casgevy Revenue Actually Flowing Through

CRISPR Therapeutics AG (CRSP) is scheduled to report first-quarter 2026 earnings on May 5, 2026, with analysts expecting a loss of $-1.14 per share. The central question for investors is whether the gene-editing pioneer can demonstrate meaningful progress in commercializing its therapies and narrowing losses after a volatile earnings track record that has seen the company alternate between beats and misses over the past year. With the stock trading near its 200-day moving average and options pricing a 5.55% expected move, this report will be critical in determining whether CRSP can sustain momentum or face another post-earnings selloff.

Part 1: Earnings Preview

CRISPR Therapeutics is a Swiss-American biotechnology company focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform, with its lead therapy Casgevy (for sickle cell disease and beta-thalassemia) representing a landmark achievement as the first CRISPR-based treatment approved for clinical use. The company operates primarily in the gene-editing therapeutics space, with a pipeline spanning hemoglobinopathies, immuno-oncology, regenerative medicine, and in vivo gene editing programs.

CRISPR Therapeutics will report first-quarter 2026 results on May 5, 2026, with the consensus estimate calling for a loss of $-1.14 per share from 9 analysts. The company most recently reported fourth-quarter 2025 results showing a loss of $-1.37 per share, which missed estimates by 19.13%. Compared to the same quarter last year (Q1 2025), when CRSP posted a loss of $-1.58 per share, the current estimate of $-1.14 represents a 27.85% improvement year-over-year, suggesting analysts expect the company to make meaningful progress in narrowing its losses.

Three key themes define this earnings story:

Casgevy Commercial Ramp: The primary focus for investors is the commercial trajectory of Casgevy, the company's approved CRISPR therapy developed in partnership with Vertex Pharmaceuticals. With the treatment now available in multiple markets, investors will scrutinize patient starts, revenue recognition timing, and any commentary on the therapy's uptake among eligible sickle cell disease and beta-thalassemia patients. The pace of commercialization will be critical in determining whether CRSP can transition from a pure R&D story to a revenue-generating biotech.

Pipeline Progress and Clinical Milestones: Beyond Casgevy, analysts are watching for updates on CRSP's broader pipeline, particularly its CAR-T programs in oncology and next-generation in vivo editing platforms. Any data readouts, regulatory submissions, or partnership announcements could significantly impact the stock, as the company needs to demonstrate that its CRISPR platform can generate multiple commercial products beyond its first approval.

Cash Burn and Runway: With the company still operating at a loss, investors will closely examine operating expenses, R&D spending, and cash burn rate. The balance between investing in pipeline development and managing cash runway is crucial, especially as CRSP navigates the expensive transition from clinical-stage biotech to commercial-stage company. Any guidance on when the company expects to reach profitability or cash flow breakeven will be closely watched.

Analyst commentary ahead of the release reflects cautious optimism tempered by execution concerns. The 15 Strong Buy ratings among 28 total analysts suggest significant long-term conviction in CRISPR's platform technology, while the 11 Hold ratings indicate that near-term catalysts and commercial execution remain question marks. The wide range of price targets—from a low of $33.00 to a high of $291.00—underscores the binary nature of biotech investing and the uncertainty around CRSP's commercial trajectory.

Part 2: Historical Earnings Performance

CRISPR Therapeutics has demonstrated an inconsistent earnings track record over the past four quarters, alternating between beats and misses with no clear pattern. In Q1 2025, the company reported a loss of $-1.58 versus an estimate of $-1.27, missing by 24.41%. The following quarter (Q2 2025) saw a reversal, with CRSP posting a loss of $-1.29 against expectations of $-1.47, beating by 12.24%. This positive momentum continued into Q3 2025, when the company reported $-1.17 versus an estimate of $-1.32, delivering another beat of 11.36%.

However, the most recent quarter (Q4 2025) saw CRSP revert to a miss, reporting a loss of $-1.37 against the consensus of $-1.15, falling short by 19.13%. This back-and-forth pattern suggests that CRSP's financial performance remains difficult to forecast, likely reflecting the lumpy nature of biotech revenue recognition, variable R&D spending, and the early-stage commercialization of Casgevy. The two consecutive beats in Q2 and Q3 2025 raised hopes that the company was finding its footing, but the significant Q4 miss has reignited concerns about execution and the predictability of the business model.

The magnitude of surprises has been substantial, ranging from a 24.41% miss to a 12.24% beat, indicating that analyst estimates have struggled to capture the company's quarterly dynamics. For the upcoming Q1 2026 report, investors should be prepared for potential volatility, as CRSP's track record suggests that consensus estimates may not reliably predict actual results. The company's ability to deliver a beat—particularly after the disappointing Q4 2025 miss—will be crucial in restoring confidence in its commercial execution and financial trajectory.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

CRISPR Therapeutics typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

CRISPR Therapeutics has exhibited significant post-earnings volatility, with an average absolute Day 0 move of 3.52% and Day +1 move of 3.85%, though individual reactions have varied widely depending on the magnitude of the earnings surprise. The most dramatic recent move came after the May 2025 report, when the stock dropped 11.86% on Day 0 following a substantial earnings miss, then recovered partially with a 3.29% gain on Day +1. Conversely, the February 2025 report—which delivered a significant earnings beat—saw a muted 0.53% Day 0 move but a strong 9.29% rally on Day +1 as investors digested the positive results.

The February 2026 report (most recent) showed a 1.26% Day 0 gain followed by a much larger 8.46% Day +1 surge, despite the company missing estimates by 19.13%, suggesting that other factors such as pipeline updates or forward guidance may have overshadowed the headline miss. The August 2025 report demonstrated the opposite pattern, with a 6.24% Day 0 gain that reversed into a 6.71% Day +1 decline, indicating that initial optimism gave way to disappointment upon closer examination of the results.

Overall, CRSP's post-earnings price action has been characterized by substantial two-day ranges averaging 6.72% on Day 0 and 6.59% on Day +1, reflecting the high-stakes nature of biotech earnings where commercial progress, pipeline updates, and cash burn can dramatically shift investor sentiment. Investors should be prepared for significant volatility in both directions, with the direction of the move likely depending not just on the EPS beat or miss, but on the quality of revenue growth, pipeline commentary, and management guidance.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 5.55% for the upcoming earnings release, which is notably higher than the average historical Day 0 move of 3.52% but somewhat lower than the average Day +1 move of 3.85%. This suggests options traders are anticipating above-average volatility compared to typical Day 0 anticipatory moves, but are not pricing in the extreme reactions seen in some recent quarters (such as the 11.86% Day 0 drop in May 2025 or the 8.46% Day +1 surge in February 2026). The 5.55% expected move appears to reflect a balanced view of potential outcomes, positioning between the more muted reactions and the dramatic swings that have characterized CRSP's recent earnings history.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on CRISPR Therapeutics, with the consensus rating at 4.07 out of 5.00 (between Hold and Buy) and an average price target of $80.91, representing 51.0% upside from the current price of $53.58. The analyst community is notably divided, with 15 Strong Buy ratings and 1 Moderate Buy reflecting significant bullish conviction, while 11 Hold ratings and 1 Moderate Sell indicate that a substantial portion of analysts are taking a wait-and-see approach. No analysts currently rate the stock a Strong Sell, suggesting that even skeptics see limited downside risk at current levels.

The sentiment trend has remained unchanged over the past month, with the distribution of ratings holding steady at 15 Strong Buys, 1 Moderate Buy, 11 Holds, and 1 Moderate Sell. This stability suggests that analysts are maintaining their positions heading into the earnings report, neither upgrading in anticipation of positive results nor downgrading due to concerns. The lack of recent rating changes may indicate that analysts are waiting for the Q1 2026 results and management commentary before making significant revisions to their outlooks.

The wide disparity in price targets—ranging from a low of $33.00 to a high of $291.00—underscores the binary nature of CRISPR Therapeutics as an investment. The bulls see the company's pioneering CRISPR platform and Casgevy's commercial potential as justifying valuations nearly five times higher than the bears, who likely focus on execution risks, cash burn, and the competitive landscape in gene editing. The mean target of $80.91 implies that the consensus view sees meaningful upside, but investors should recognize that outcomes could vary dramatically depending on commercial execution, pipeline progress, and the company's ability to demonstrate a clear path to profitability. The upcoming earnings report will be a key test of whether the bullish thesis is gaining traction or whether the more cautious Hold-rated analysts will be vindicated.

Part 4: Technical Picture

CRISPR Therapeutics enters its earnings report with a deteriorating technical picture, as the Barchart Technical Opinion has weakened significantly in recent weeks. The current signal stands at 16% Sell, a dramatic decline from 96% Sell one week ago and 88% Sell one month ago. This sharp reversal from extreme oversold conditions to a more neutral bearish reading suggests the stock has experienced a technical bounce, but the underlying trend remains fragile.

Timeframe Analysis:

• Short-term (50% Buy): Neutral-to-slightly-bullish signal indicates near-term momentum has stabilized after recent weakness, suggesting the stock may have found temporary support
• Medium-term (50% Sell): Neutral-to-slightly-bearish reading suggests the intermediate trend remains under pressure, with no clear directional conviction
• Long-term (50% Sell): Neutral-to-slightly-bearish signal reflects ongoing weakness in the longer-term trend, indicating the stock has not established a sustainable uptrend

Trend Characteristics: The technical environment is characterized by Minimum strength with a Weakening direction, suggesting that while the stock has bounced from oversold levels, the underlying trend lacks conviction and remains vulnerable to renewed selling pressure heading into earnings.

The stock is currently trading at $53.58, positioned above its 5-day ($52.06), 10-day ($52.72), 20-day ($53.57), 50-day ($52.47), and 100-day ($53.29) moving averages, but below its critical 200-day moving average of $56.45. This configuration suggests the stock has experienced a short-term recovery that has lifted it above most near-term moving averages, but it remains below the key long-term trend indicator. The 200-day moving average at $56.45 represents a significant resistance level that CRSP would need to reclaim to signal a more durable reversal of its longer-term downtrend.

The proximity to the 200-day moving average makes this earnings report particularly consequential from a technical perspective—a strong beat and positive guidance could propel the stock above this key resistance level and potentially trigger a more sustained rally, while a disappointment could send CRSP back toward its shorter-term moving averages in the low $50s. The weak trend characteristics (Minimum strength, Weakening direction) and the neutral-to-bearish medium and long-term signals suggest the technical setup is cautionary rather than supportive heading into earnings. Traders should note that the stock's recent bounce from oversold conditions may have already priced in some optimism, leaving limited room for error if the company fails to deliver on expectations. The 5.55% expected move priced by options suggests the market is bracing for significant volatility, and the technical picture indicates that downside risk may be more pronounced than upside potential unless CRSP can deliver a clear positive surprise.